First-in-human Study of THB335, an Oral Small Molecule Inhibitor of Wild Type KIT Receptor Tyrosine Kinase: Initial Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD)[...]

Third Harmonic Bio Inc. published this content on February 26, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 25, 2025 at 21:48 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]